Tariffs on generic drugs will cause companies to stop making them: Former FDA Commissioner Gottlieb

Summary of YouTube Video Transcript

Key Concepts:

• Pharmaceutical Supply Chain
• Active Pharmaceutical Ingredients (API)
• Generic vs. Branded Drugs
• National Security Concerns
• Section 232 Provision
• Tariffs
• Drug Shortages
• FDA and Environmental Approvals
• Manufacturing Incentives
• Trade Deficit

Pharmaceutical Manufacturing Landscape in the US

• Domestic Manufacturing: Approximately 50% of drugs consumed in the US are manufactured domestically in about 300 registered facilities.
• Puerto Rico: 10% of drugs consumed in the US are manufactured in Puerto Rico.
• European Imports: The majority of the remaining 50% of drugs are imported from Europe, contributing significantly to the US trade deficit.
• Ireland: $50 billion of the $235 billion trade deficit with Europe is attributed to drugs imported from Ireland, where many branded drugs are manufactured due to tax advantages.

National Security Concerns and China's Role

• Focus on Generics: The national security concerns primarily revolve around the US reliance on China for antibiotics and basic generic medicines, including life-saving drugs like heparin and amoxicillin.
• Heparin Example: 40% of the heparin used in the US is manufactured in China.
• Amoxicillin Example: Largely all the amoxicillin used in the US is made in China.
• Key Starting Materials: 70% of key starting materials for pharmaceuticals originate in China.

Potential Impact of Tariffs on Generic Drugs

• Price Increases and Shortages: Imposing tariffs on generic drugs from China could lead to price increases and, more critically, drug shortages.
• Slim Margins: Generic drug manufacturers operate on very slim margins and may exit the market if tariffs are imposed.
• Limited Cushion: Unlike branded drug companies, generic manufacturers have limited financial flexibility to absorb tariff costs or shift manufacturing.

Alternative Strategies to Tariffs

• Expedited Approvals: Expediting FDA and environmental approvals for domestic manufacturing facilities is crucial.
• Grand Bargain with Branded Industry: The President could negotiate with branded drug companies to incentivize them to bring manufacturing back from Europe (specifically Ireland).
• Tax Advantages vs. Other Factors: While tax advantages in Ireland are a draw, factors like cheaper energy and easier labor in the US make domestic manufacturing more attractive.
• Lilly and Novartis: Examples of companies that have recently announced plans to bring manufacturing back to the US.

Addressing the China-Based Supply Chain

• Complex Supply Chain: Moving the entire supply chain from China and India (where key starting materials from China are finished into APIs) to the US is challenging.
• Regulatory Barriers and Subsidies: Requires reducing regulatory barriers and potentially providing targeted subsidies to incentivize domestic manufacturing.
• Low-Margin Products: Generic drug companies often sell these drugs at a loss to secure other business, making it difficult to justify domestic manufacturing without support.

Section 232 Provision and Bifurcated Approach

• National Security Provision: The Section 232 provision, intended to address national security concerns, may be counterproductive when applied to generic drugs.
• Bifurcated Approach: The speaker suggests treating the European issue (trade deficit) separately from the China issue (national security).
• Different Solutions: Each issue requires a different solution tailored to its specific challenges.

Conclusion

The speaker argues against using tariffs on generic drugs from China, warning of potential price increases and drug shortages. Instead, they advocate for a bifurcated approach: negotiating with branded drug companies to bring manufacturing back from Europe through expedited approvals and incentives, and addressing the China-based supply chain through regulatory reform and targeted subsidies to encourage domestic generic drug manufacturing. The key takeaway is that a nuanced strategy is needed to address both the trade deficit with Europe and the national security concerns related to pharmaceutical supply chains in China and India.